Momentum is building for biosimialrs but robust coverage for lower-cost agents, including biosimilars, is needed.
Jeff Baldetti
Advertisement
Articles by Jeff Baldetti
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Johns Hopkins experts warn of potentially severe flu season, measles elimination status faces risk
2
Many PCPs unaware of current ACIP shingles vaccine guidance, study finds
3
Will the end of enhanced ACA subsidies mean the beginning of a health insurance crisis?
4
Top 5 most-read stories out of the 2025 AAD annual meeting
5